The LKB1-AMPK Pathway-Friend or Foe in Cancer?

    Research output: Contribution to journalEditorial

    44 Citations (Scopus)

    Abstract

    Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.

    Original languageEnglish
    Pages (from-to)131-132
    Number of pages2
    JournalCancer Cell
    Volume23
    Issue number2
    Early online date11 Feb 2013
    DOIs
    Publication statusPublished - 11 Feb 2013

    Keywords

    • METFORMIN
    • AMPK
    • KINASE

    Cite this

    @article{2f3027506abf45bb89c145235736cf3d,
    title = "The LKB1-AMPK Pathway-Friend or Foe in Cancer?",
    abstract = "Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.",
    keywords = "METFORMIN, AMPK, KINASE",
    author = "Hardie, {D. Grahame}",
    note = "Preview. No funding",
    year = "2013",
    month = "2",
    day = "11",
    doi = "10.1016/j.ccr.2013.01.009",
    language = "English",
    volume = "23",
    pages = "131--132",
    journal = "Cancer Cell",
    issn = "1535-6108",
    publisher = "Elsevier",
    number = "2",

    }

    The LKB1-AMPK Pathway-Friend or Foe in Cancer? / Hardie, D. Grahame.

    In: Cancer Cell, Vol. 23, No. 2, 11.02.2013, p. 131-132.

    Research output: Contribution to journalEditorial

    TY - JOUR

    T1 - The LKB1-AMPK Pathway-Friend or Foe in Cancer?

    AU - Hardie, D. Grahame

    N1 - Preview. No funding

    PY - 2013/2/11

    Y1 - 2013/2/11

    N2 - Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.

    AB - Use of the biguanide metformin, an AMPK activator, is associated with a reduced incidence of cancer in diabetics, but it has been unclear whether this requires AMPK. In this issue of Cancer Cell, Shackelford and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse tumors that lack a functional LKB1-AMPK pathway.

    KW - METFORMIN

    KW - AMPK

    KW - KINASE

    U2 - 10.1016/j.ccr.2013.01.009

    DO - 10.1016/j.ccr.2013.01.009

    M3 - Editorial

    VL - 23

    SP - 131

    EP - 132

    JO - Cancer Cell

    JF - Cancer Cell

    SN - 1535-6108

    IS - 2

    ER -